Head-to-head evidence
BAY3283142 vs Riociguat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Soluble guanylate cyclase · full Hypertension pipeline
BAY3283142
Developed by Bayer
NCT05491642 · Phase 1 · completed
This was a randomized, placebo-controlled study with single-blinding, but it measured only adverse events rather than a disease outcome like blood pressure change, and no results have been posted yet. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Riociguat · Adempas
Marketed by Bayer
NCT00810693 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled trial with 445 randomized participants. The hard clinical primary endpoint, change in six-minute walking distance at week 12, was met for the higher-dose riociguat group versus placebo (p<0.0001).
Next expected readout: January 2031 · NCT07644377 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAY3283142's landscape · Riociguat's landscape